Literature DB >> 15348953

In vivo bone formation by human bone marrow cells: effect of osteogenic culture supplements and cell densities.

S C Mendes1, I Van Den Brink, J D De Bruijn, C A Van Blitterswijk.   

Abstract

Bone marrow is known to contain a population of osteoprogenitor cells that can go through complete differentiation when cultured in a medium containing appropriate bioactive factors. In this study, porous particles of a calcium phosphate material were seeded with adult human bone marrow cells in the second passage. After an additional culture period of 1 wk in the particles, these hybrid constructs were subcutaneouslly implanted in nude mice with a survival period of 4 wk. The cell seeding densities range from 0-200 000 cells per particle and the cell culture system was designed to investigate the single and combined effects of dexamethasone and recombinant human bone morphogenetic protein 2 (rhBMP-2). The hybrid "material/tissue" constructs were processed for histology and the amount of de novo bone formation was quantified, for each culture condition, by histomorphometric techniques. The relative percentage of mineralized bone formation reached a maximal value of 19.77+/-5.06, for samples cultured in the presence of rhBMP-2 and with a seeding density of 200 000 cells/particle, compared to 0.52+/-0.45 for samples in which no cells had been cultured and had been incubated in culture medium supplemented with Dex and rhBMP-2. For the tested conditions and for the low cell numbers used in this study, rhBMP-2 proved to be an essential bioactive factor to obtain in vivo bone formation by our culture system. The results from this study prove the potential of cultured adult human bone marrow cells to initiate and accelerate de novo bone formation after transplantation into an ectopic site. Copyright 1998 Kluwer Academic Publishers

Entities:  

Year:  1998        PMID: 15348953     DOI: 10.1023/a:1008904413859

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  20 in total

1.  Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts.

Authors:  P H Krebsbach; S A Kuznetsov; K Satomura; R V Emmons; D W Rowe; P G Robey
Journal:  Transplantation       Date:  1997-04-27       Impact factor: 4.939

2.  Effects of recombinant human bone morphogenetic protein-2 on human bone marrow cells cultured with various biomaterials.

Authors:  K J Kim; T Itoh; S Kotake
Journal:  J Biomed Mater Res       Date:  1997-06-05

Review 3.  Osteogenic stem cells and the stromal system of bone and marrow.

Authors:  J N Beresford
Journal:  Clin Orthop Relat Res       Date:  1989-03       Impact factor: 4.176

4.  Characterization of cells with high alkaline phosphatase activity derived from human bone and marrow: preliminary assessment of their osteogenicity.

Authors:  B A Ashton; F Abdullah; J Cave; M Williamson; B C Sykes; M Couch; J W Poser
Journal:  Bone       Date:  1985       Impact factor: 4.398

5.  Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats.

Authors:  C Maniatopoulos; J Sodek; A H Melcher
Journal:  Cell Tissue Res       Date:  1988-11       Impact factor: 5.249

6.  Bone marrow-derived stromal cell line expressing osteoblastic phenotype in vitro and osteogenic capacity in vivo.

Authors:  D Benayahu; Y Kletter; D Zipori; S Wientroub
Journal:  J Cell Physiol       Date:  1989-07       Impact factor: 6.384

7.  Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures.

Authors:  A Herbertson; J E Aubin
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

8.  Dexamethasone recruitment of self-renewing osteoprogenitor cells in chick bone marrow stromal cell cultures.

Authors:  N Kamalia; C A McCulloch; H C Tenebaum; H Limeback
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

9.  Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells.

Authors:  R S Thies; M Bauduy; B A Ashton; L Kurtzberg; J M Wozney; V Rosen
Journal:  Endocrinology       Date:  1992-03       Impact factor: 4.736

10.  Recombinant human bone morphogenetic protein (rhBMP) induced heterotopic bone development in vivo and in vitro.

Authors:  H Volek-Smith; M R Urist
Journal:  Proc Soc Exp Biol Med       Date:  1996-03
View more
  6 in total

1.  A cultured living bone equivalent enhances bone formation when compared to a cell seeding approach.

Authors:  S C Mendes; M Sleijster; A Van Den Muysenberg; J D De Bruijn; C A Van Blitterswijk
Journal:  J Mater Sci Mater Med       Date:  2002-06       Impact factor: 3.896

2.  Interactions of total bone marrow cells with increasing quantities of macroporous calcium phosphate ceramic granules.

Authors:  Damien Le Nihouannen; Laure Duval; Antoine Lecomte; Marion Julien; Jérôme Guicheux; Guy Daculsi; Pierre Layrolle
Journal:  J Mater Sci Mater Med       Date:  2007-06-07       Impact factor: 3.896

3.  Stem cell-based bone repair.

Authors:  Yurong Fei; Ren-He Xu; Marja M Hurley
Journal:  Am J Stem Cells       Date:  2012-05-18

4.  Effect of cell seeding density on proliferation and osteodifferentiation of umbilical cord stem cells on calcium phosphate cement-fiber scaffold.

Authors:  Hongzhi Zhou; Michael D Weir; Hockin H K Xu
Journal:  Tissue Eng Part A       Date:  2011-07-11       Impact factor: 3.845

5.  Relation between in vitro and in vivo osteogenic potential of cultured human bone marrow stromal cells.

Authors:  S C Mendes; J M Tibbe; M Veenhof; S Both; F C Oner; C A van Blitterswijk; J D de Bruijn
Journal:  J Mater Sci Mater Med       Date:  2004-10       Impact factor: 3.896

6.  Optimizing In Vitro Osteogenesis in Canine Autologous and Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells with Dexamethasone and BMP-2.

Authors:  Shelby B Gasson; Lauren K Dobson; Lyndah Chow; Steven Dow; Carl A Gregory; William Brian Saunders
Journal:  Stem Cells Dev       Date:  2021-02-08       Impact factor: 3.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.